Has Justin Gainor, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,166,822 in general payments to Justin Gainor, MD across 607 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Justin Gainor, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Justin Gainor, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Justin Gainor, MD

Medical Oncology · Boston, MANPI 1487813010

Payments from drug & device makers

$8,166,822in general payments, 2019–2025

Across 607 payments — averaging $13,454 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$5.1M
E.r. Squibb & Sons, L.L.C.$696K
Novartis$670K
Modernatx, Inc.$490K
Blueprint Medicines Corporation$359K
Array Biopharma Inc$149K
plus $743K from 38 others

$11,139in research payments, 2019–2025

Across 8 payments — averaging $1392.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$6K
F. Hoffmann-la Roche AG$5K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	200	$5,060,310
E.r. Squibb & Sons, L.L.C.	35	$696,170
Novartis	27	$669,894
Modernatx, Inc.	70	$490,424
Blueprint Medicines Corporation	33	$358,719
Array Biopharma Inc	5	$148,660
Roche Products Limited	8	$135,502
Genentech, Inc.	12	$81,700
Pfizer	38	$74,466
Hoffmann-la Roche Limited	7	$68,722
Beigene USA, Inc.	14	$65,125
AstraZeneca	22	$54,069
Takeda Pharmaceuticals U.S.A., Inc.	20	$40,876
Genentech USA, Inc.	15	$26,280
Helsinn Healthcare SA	3	$25,678
GSK	6	$21,156
Tesaro, Inc.	11	$20,993
Beone Medicines Ltd.	4	$19,392
Eli Lilly	15	$15,268
Roche Diagnostics Corporation	5	$10,550
Beone Medicines USA, Inc.	2	$9,500
Beigene, Ltd.	4	$8,979
Gilead	8	$7,682
F. Hoffmann-la Roche AG	2	$5,890
Karyopharm Therapeutics Inc.	1	$5,000
EMD Serono, Inc.	3	$4,610
Sanofi	2	$4,578
Johnson & Johnson	4	$4,555
Janssen Scientific Affairs, LLC	2	$4,140
Daiichi Sankyo Inc.	5	$3,368
Regeneron	3	$2,721
Jazz Pharmaceuticals Inc.	2	$2,601
Beigene Switzerland GmbH	2	$2,600
Ipsen Biopharmaceuticals, Inc	1	$2,500
Mirati Therapeutics, Inc.	3	$2,363
Rigel Pharmaceuticals, Inc.	3	$2,188
Roche Molecular Systems, Inc.	1	$2,000
Ventana Medical Systems, Inc.	1	$2,000
Amgen	1	$1,947
Chugai Pharmaceutical Co., Ltd.	1	$1,320
Kowa Research Institute, Inc.	1	$1,000
Novocure Inc.	1	$685
Astrazeneca UK Limited	3	$362
Pfizer Pharma GmbH	1	$281

How this compares

$8,166,822 in reported general payments places this provider in the 90th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$81,260

Medicare patients

171

Services billed

809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

Otto MetzgerBoston$141.9M
Suzanne GeorgeBoston$88.5M
Pasi Antero JanneBoston$67.2M
Erica MayerBoston$51.8M
Toni ChoueiriBoston$28.3M
Laura SpringBoston$22.9M
James ClearyBoston$18.8M
Marlise LuskinBoston$18.7M
Ana Garrido-CastroBoston$18M
Jacob LaubachBoston$17.9M

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →